## Meehyein Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3760828/publications.pdf

Version: 2024-02-01

		361413	302126
56	1,593	20	39
papers	citations	h-index	g-index
59	59	59	2807
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I. Molecular Therapy, 2007, 15, 1145-1152.	8.2	159
2	In vitro inhibition of influenza A virus infection by marine microalga-derived sulfated polysaccharide p-KG03. Antiviral Research, 2012, 93, 253-259.	4.1	143
3	Inhibition of influenza virus internalization by (â^')-epigallocatechin-3-gallate. Antiviral Research, 2013, 100, 460-472.	4.1	108
4	Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. Journal of Hepatology, 2009, 50, 479-488.	3.7	82
5	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Pro inhibitors. Antiviral Research, 2017, 141, 101-106.	4.1	77
6	Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2. Scientific Reports, 2021, 11, 821.	3.3	70
7	Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. Viruses, 2018, 10, 283.	3.3	69
8	Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral Research, 2015, 124, 1-10.	4.1	59
9	A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication. Chemical Communications, 2014, 50, 368-370.	4.1	58
10	Efficient synthesis of 3 H ,3 $\hat{a}$ $\in$ 2 H -spiro[benzofuran-2,1 $\hat{a}$ $\in$ 2-isobenzofuran]-3,3 $\hat{a}$ $\in$ 2-dione as novel skeletons specifically for influenza virus type B inhibition. European Journal of Medicinal Chemistry, 2013, 62, 534-544.	5.5	50
11	Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function. Journal of Virology, 2018, 92, .	3.4	50
12	Characterization and mechanisms of anti-influenza virus metabolites isolated from the Vietnamese medicinal plant Polygonum chinense. BMC Complementary and Alternative Medicine, 2017, 17, 162.	3.7	41
13	Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Research, 2006, 122, 1-10.	2.2	39
14	Template Requirements for De Novo RNA Synthesis by Hepatitis C Virus Nonstructural Protein 5B Polymerase on the Viral X RNA. Journal of Virology, 2002, 76, 6944-6956.	3.4	37
15	Evaluation and Clinical Validation of Two Field–Deployable Reverse Transcription-Insulated Isothermal PCR Assays for the Detection of the Middle East Respiratory Syndrome–Coronavirus. Journal of Molecular Diagnostics, 2017, 19, 817-827.	2.8	35
16	Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Research, 2006, $119$ , $146-153$ .	2.2	33
17	Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. Biochemical and Biophysical Research Communications, 2009, 378, 192-196.	2.1	33
18	CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. Journal of Biological Chemistry, 2017, 292, 10664-10671.	3.4	33

#	Article	IF	Citations
19	Antiviral activity of micafungin against enterovirus 71. Virology Journal, 2016, 13, 99.	3.4	30
20	Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. Rna, 2009, 15, 898-910.	3 <b>.</b> 5	29
21	Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro. Scientific Reports, 2019, 9, 8682.	3.3	23
22	Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochemical and Biophysical Research Communications, 2007, 364, 436-442.	2.1	21
23	Branched, Tripartite-Interfering RNAs Silence Multiple Target Genes with Long Guide Strands. Nucleic Acid Therapeutics, 2012, 22, 30-39.	3.6	20
24	Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules, 2021, 26, 7420.	3.8	20
25	Comparison of Antiviral Activity of Gemcitabine with 2′-Fluoro-2′-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. International Journal of Molecular Sciences, 2021, 22, 1581.	4.1	18
26	BC200 RNA: An Emerging Therapeutic Target and Diagnostic Marker for Human Cancer. Molecules and Cells, 2018, 41, 993-999.	2.6	18
27	Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones. Antiviral Research, 2014, 107, 66-75.	4.1	17
28	Aminoglycoside antibiotics bind to the influenza A virus RNA promoter. Molecular BioSystems, 2012, 8, 2857.	2.9	16
29	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. Journal of Medicinal Chemistry, 2015, 58, 9546-9561.	6.4	16
30	Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins. Antiviral Research, 2016, 134, 77-88.	4.1	14
31	Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. Biomaterials, 2022, 283, 121460.	11.4	14
32	Development of a Subtype-Specific Diagnostic System for Influenza Virus H3N2 Using a Novel Virus-Based Systematic Evolution of Ligands by Exponential Enrichment (Viro-SELEX). Journal of Biomedical Nanotechnology, 2019, 15, 1609-1621.	1.1	13
33	Effects of C5 Protein on Escherichia coli RNase P Catalysis with a Precursor tRNAPhe Bearing a Single Mismatch in the Acceptor Stem. Biochemical and Biophysical Research Communications, 2000, 268, 136-140.	2.1	12
34	Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Reports, 2020, 53, 166-171.	2.4	12
35	Structural requirements for assembly and homotypic interactions of the hepatitis C virus core protein. Virus Research, 2006, 122, 137-143.	2.2	11
36	Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. Journal of Microbiology, 2017, 55, 979-983.	2.8	11

#	Article	IF	Citations
37	Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2533-2538.	2.2	11
38	Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Medicinal Chemistry Letters, 2021, 12, 242-248.	2.8	11
39	TRIM Proteins and Their Roles in the Influenza Virus Life Cycle. Microorganisms, 2020, 8, 1424.	3.6	10
40	In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. Viruses, 2020, 12, 581.	3.3	10
41	Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. European Journal of Medicinal Chemistry, 2020, 188, 112031.	5.5	9
42	Effects of Terminal Deletions in C5 Protein on Promoting RNase P Catalysis. Biochemical and Biophysical Research Communications, 2000, 268, 118-123.	2.1	8
43	Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Research, 2018, 46, 1635-1647.	14.5	7
44	Antiviral Activity of Isoquinolone Derivatives against Influenza Viruses and Their Cytotoxicity. Pharmaceuticals, 2021, 14, 650.	3.8	5
45	Biophysical characterization of sites of host adaptive mutation in the influenza A virus RNA polymerase PB2 RNA-binding domain. International Journal of Biochemistry and Cell Biology, 2014, 53, 237-245.	2.8	4
46	Discrimination between target and non-target interactions on the viral surface by merging fluorescence emission into Rayleigh scattering. Nanoscale, 2020, 12, 7563-7571.	5.6	4
47	Brain Cytoplasmic RNAs in Neurons: From Biosynthesis to Function. Biomolecules, 2020, 10, 313.	4.0	4
48	Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. Nucleic Acids Research, 2018, 46, 10533-10533.	14.5	3
49	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorganic and Medicinal Chemistry, 2020, 28, 115679.	3.0	3
50	The efficacy of a 2,4-diaminoquinazoline compound as an intranasal vaccine adjuvant to protect against influenza A virus infection in vivo. Journal of Microbiology, 2022, 60, 550-559.	2.8	3
51	Membrane-based hybridization capture of intracellular peptide nucleic acid. Analytical Biochemistry, 2010, 399, 135-137.	2.4	2
52	Electrochemical Synthesis of 3D Plasmonicâ€Molecule Nanocomposite Materials for In Situ Labelâ€Free Molecular Detections. Advanced Materials Interfaces, 2021, 8, 2101201.	3.7	2
53	Determination of the vRNA and cRNA promoter activity by M segment-specific non-coding nucleotides of influenza A virus. RNA Biology, 2021, $18$ , $785$ - $795$ .	3.1	1
54	Heterogeneous Sequences of Brain Cytoplasmic 200 RNA Formed by Multiple Adenine Nucleotide Insertions. Molecules and Cells, 2019, 42, 495-500.	2.6	1

#	Article	IF	CITATIONS
55	Structural and biophysical properties of RIG-I bound to dsRNA with G-U wobble base pairs. RNA Biology, 2020, 17, 325-334.	3.1	o
56	Heterogeneous Sequences of Brain Cytoplasmic 200 RNA Formed by Multiple Adenine Nucleotide Insertions. Molecules and Cells, 2019, 42, 495-500.	2.6	0